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Saphenous vein graftObjective: To evaluate the long-term clinical results of bare stents (BMS) and drug eluting stents (DES) for the
treatment of saphenous vein graft (SVG) lesions, to examine the efﬁcacy and safety of both and to determine
the parameters that have predictive value for long term clinical results.
Methods: Between 2009 and 2011, the long-term results were examined and compared respectively in 107
patients with SVG lesions on whom revascularization was applied using BMS or DES.
Results: The long-term results of BMS (n: 56) andDES groups (n: 51)were compared (average follow-up time for
both groups: 22.1± 10.7months). At one-year follow-up, the BMS group had higher target vessel revasculariza-
tion (TVR) (33.9% vs 11.8%, p= .01) andmajor adverse cardiac events (MACE) (35.7% vs 15.7%, p: .02) compared
to theDES group. Therewere no signiﬁcant differences inmyocardial infarction (MI) andmortality rates between
the two groups. At a median follow-up of 2 years, there were no signiﬁcant differences in composite MACE, TVR,
MI and mortality rates between the two groups. Event free survival at 1 and 2 years was 84.3%, 66.7% vs 64.3%,
50% for DES and BMS group, respectively.
Conclusion: At one year follow-up, patients receiving DES had signiﬁcantly better clinical outcomes than their
BMS counterparts. However, long term outcomes among the two groups were similar.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved.
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Since the ﬁrst coronary artery bypass operation by Favaloro in 1968,
the improvements in revascularization have been continuing toıcıYoluKiptaşMerkez Evleri A7
diovascular Academy.
my. Production and hosting by Elseaccelerate.1 However, the fragile structure, degeneration and occlusion
that were seen in SVG have emerged as long-term problems. The devel-
opment of stenosis or occlusion in SVG in 15% during the ﬁrst year and
50% in 10 years has revealed that new techniques must be used.2 The
initial implementation of balloon angioplasty has been superseded by
direct stent implantation due to low success, high restenosis rates and
increases in MACE in the former. In 1998, Figulla et al. obtained better
results in clinical applications via introducing direct stent technique
without angioplasty.3 Advances in stent technology paved the way forvier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Table 2
Lesion and procedural characteristics.
Parameters BMS group (n: 56) DES group (n: 51) p
Number of stents, n (%) 1.8 ± 0.9 1.7 ± 0.9 0.688
Diameter stenosis, % 86.0 ± 11 95.0 ± 0.3 0.548
Stent diameter, mm 3.2 ± 0.6 3.1 ± 0.5 0.791
Stent length, mm 17.5 ± 6.0 25.8 ± 11.9 0.030
Maximum balloon pressure (atm.) 13.3 ± 1.6 14.0 ± 4.2 0.718
No reﬂow, n (%) 4 (7.1) 3 (5.8) 0.771
Angiographic success, n (%) 54 (96.4) 50 (98) 0.876
BMS, bare metal stent; DES, drug eluting stent.
Bold values indicate signiﬁcance at p b 0.05.
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ﬂicting results on BMS and DES application results in saphenous vein
grafts. In the short term, SVG revascularization with BMS resulted in
high rates of restenosis.4,5 Although short term restenosis rates were
found signiﬁcantly lowerwithDES, the studies reported that this beneﬁt
disappeared in the long term and the mortality rate increased.6–9 Al-
though there is consensus on short term results, more comprehensive
research is needed on long term results. In this study, we compare the
long term results of BMS and DES implantations in saphenous vein
grafts, and determine the parameters that have predictive value for
MACE.
Methods
Between 2009 and 2011, 107 patients who received percutaneous
coronary intervention (PCI) due to SVG lesionswere retrospectively an-
alyzed. The investigations were performed by two experienced cardiol-
ogists. Patient data was obtained from medical records, telephone
contact and outpatient examinations. After a detailed history had been
taken, their physical examinations were performed. All patients, who
underwent at least one exercise stress test and myocardial perfusion
scintigraphy (99mTc-MIBI) for the investigation of ischemia were
included in the study. Patients who had signs of ischemia received cor-
onary angiography as the standard approach. The patients were admin-
istered 325mg/day of aspirin, 600mg clopidogrel, if the patients are not
on it, and 100 units/kg of heparin administered before the procedure to
reach the target clotting time (ACT) of 250–300 s. Biochemical analysis
of blood samples is held before the procedure. 56 applied BMS and 51
patients applied DES. The dates when the ﬁrst and the last applications
done to the patients are recorded and their total monitoring times were
calculated. All patients received clopidogrel and aspirin for 1 year and
only aspirin after that.
Deﬁnitions
MACE was deﬁned as a sum of cardiac death, myocardial infarction,
target vessel revascularization (TVR). Target lesion revascularization
(TLR); revascularization procedure for lesions that have more than
50% stenosis within the stent, 5 mm proximal or distal to the stent.
Stent thromboses were evaluated according to the criteria deﬁned by
the Academic Research Consortium.10 The diagnosis of myocardial
infarction required 2 of the following: 1) prolonged (N30 min) chest
pain; 2) a rise in creatine kinase levels more than twice the local
upper normal value (with abnormal MB fraction); and 3) developmentTable 1
Baseline clinical characteristics.
Parameters BMS group (n: 56) DES group (n: 51) p
Age (years) 63.1 ± 6.8 64.2 ± 8.1 0.747
Male, n (%) 44 (78.6) 36 (70.6) 0.379
Female, n (%) 12 (21.4) 15 (29.4)
Hypertension, n (%) 38 (67.8) 31 (60.7) 0.874
Diabetes mellitus, n (%) 18 (32.1) 19 (37.2) 0.252
Smoking, n (%) 29 (63.0) 5 (55.6) 0.719
SVG age (years) 8.0 ± 6.3 7.5 ± 3.6 0.879
SVG vessels, n 3.4 ± 0.7 3.3 ± 1.3 0.478
Beta blocker, n (%) 42 (75) 40 (78.4) 0.885
Statin, n (%) 41 (73.2) 40 (78.4) 0.775
Hematologic parameters
MPV (μm3) 8.7 ± 9 8.9 ± 1.5 0.737
PDW (%) 16.3 ± 11.0 13.4 ± 1.2 0.06
NLR 2.7 ± 1.2 2.2 ± 0.6 0.323
RDW (%) 14.1 ± 1.8 12.9 ± 1.8 0.232
Platelet count (109/l) 237.3 ± 56.3 241.0 ± 65.8 0.637
SVG: saphenous vein graft, MPV:main platelet volume, PDV: platelet distribution volume,
NLR: neutrophil lymphocyte ratio, RDW: red cell distribution wide9; BMS, bare metal
stent; DES, drug eluting stent.of persistent ischemic electrocardiographic changes (with or without
new pathological Qwaves). Deaths of unknown etiology are considered
to be cardiac deaths. Procedural success was considered to be b20% of
residual stenosis and TIMI (Thrombolysis In Myocardial Infarction)
grade III ﬂow.11
Statistics
Continuous variables are expressed as mean ± SD. Categorical vari-
ables are expressed as percentages. To compare parametric continuous
variables, Student's t-test was used; to compare nonparametric contin-
uous variables, theMannWhitney U test was used; and to compare cat-
egorical variables, chi-squared test was used. Multivariate logistic
regression analysis was used to identify the independent predictor of
MACE. Event-free survival curves were generated by the Kaplan–
Meier method and differences in survival were compared using log-
rank test. All variables showing signiﬁcance values less than 0.05.
Two-tailed p values less than 0.05 were considered signiﬁcant and the
conﬁdence interval was 95%. All statistical studies were carried out
using the SPSS program (version 22.0; SPSS Inc., Chicago, Illinois, USA).
Results
Clinical and demographic characteristic of patients are shown in
Table 1. In total of 107 patients (27 women, 80 men, mean age:
62.3±7.3 years)were included in the study. Therewere similarities be-
tween these two groups in terms of demographic and clinical character-
istics and medical treatment. There were no statistical differences
between the groups in terms of age, gender, hypertension, diabetes,
and smoking. Average age of SVG was 7.73 ± 4.6 years. There was no
signiﬁcant difference between the two groups in terms of bypass graft
age and number of grafts.
Table 2 shows lesion and procedure characteristics. The number of
stents implanted per patient was 1.65 ± 8.9, with an average diameter
of 3.04±0.5mm. Stent length in theDES groupwas signiﬁcantly longer
than that in the BMS group (25. 8 ± 11.9 mm vs. 17.5 ± 6.0 mm,
p = .03). Maximum inﬂation pressure (pressure: 13.8 ± 2.0 atm.)Table 3
Clinical outcomes at long term follow-up.
Parameters BMS group (n: 56) DES group (n: 51) p
One year outcomes
Composite MACE, n (%) 20 (35.7) 8 (15.7) 0.02
TVR, n (%) 19 (33.9) 6 (11.8) 0.01
Myocardial infarction, n (%) 5 (9.1) 4 (8) 1.00
Mortality, n (%) 2 (3.6) 1 (2) 1.00
Total follow up time outcomes
Composite MACE, n (%) 30 (53.6) 18 (35.3) 0.08
TVR, n (%) 22 (39.3) 14 (27.5) 0.223
Myocardial infarction, n (%) 9 (16.1) 7 (813.7) 0.791
Mortality, n (%) 3 (5.4) 2 (3.9) 1.00
MACE: major adverse cardiac event, TVR: target vessel revascularization; BMS, baremetal
stent; DES, drug eluting stent.
Table 4
Multivariate predictors of composite MACE.
OR 95% CI p
Hypertension 0.072 0.023–0.225 0.00
Diabetes mellitus 0.346 0.151–790 0.01
SVG age 0.983 0.852–1.13 0.809
Stent length (mm) 1.04 0.993–1.14 0.08
Stent çapı (mm) 1.45 0.666–0.317 0.34
Treatment with BM or DES 2.90 1.15–7.28 0.02
CI, conﬁdence interval; OR, odds ratio; BMS, baremetal stent; DES, drug eluting stent; SVG,
saphenous vein graft.
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cases. The intervention was unsuccessful in 3 (2.8%) cases.
Table 3 shows clinical outcomes at one year and long term follow-
up. At one year follow-upmortality and risk ofMI did not differ between
DES and BMS group (9.1% vs. 8%, p= 1). However, TVR andMACE rates
were signiﬁcantly higher in the BMS group. Rates of TVR and MACE
were 33.9% vs. 11.8% (p = .01) and 35.7% vs. 15.7%, (p = .02) for the
BMS and DES groups, respectively. Rates of two year (follow-up time:
22.1 ± 10.7 months) MI, mortality, TVR and composite MACE were
not different between DES and BMS patients.
One and two year TVR rates in DES group were 11.8% and 27.5%
respectively.
Table 4 shows multivariate predictors of Composite MACE. Hyper-
tension (OR: 0.072; 95% CI: 0.023–0.225; p = .000), diabetes mellitus
(OR: 0.346; 95% CI: 0.151–0.790; p = .01) and type of stent (DES vs.
BMS) (OR: 2.90; 95% CI: 1.15–7.28; p = .02) were independent predic-
tors of composite MACE. Kaplan Meier survival curves for event free
survival at 1 and 2 years was 84.3%, 66,7% vs 64.3%, 50% for DES and
BMS group, respectively (Fig. 1).
Discussion
In saphenous vein grafts, early beneﬁt of DES seen in the ﬁrst year
was not sustained with longer-term follow-up. We found that, DES,
compared with BMS, reduced TVR in ﬁrst year, but this advantage de-
creased over time such that at 2 years. At two-year follow-up, thereFig. 1. Kaplan Meier survival curves for freedom from major adverse cardiac evenwas a 2.33 fold increase in TVR (11.8% vs. 27.5%) in DES treated patients.
These results seem to be consistentwith the results of research examin-
ing the late DES restenosis.
It is estimated that, at least 50% of SVG lesions will develop stenosis
or occlusionwithin 10 years of implantation.2 Due to the highmorbidity
and mortality of reoperations, percutaneous intervention and revascu-
larization are recommended in such cases. SVG lesions typically have a
low ﬁbrotic component and a fragile structure rich in necrotic debris,
cholesterol and foam cell. For this reason, stent therapy is emerging as
a more affordable option rather than balloon angioplasty.3
The process startedwith BMS initially, and then evolvedwith DES. In
previous studies made with BMS and DES, conﬂicting results were
found. While no differences between BMS and DES were found in
some of the studies, in others DES were found superior.6,12 In the ﬁrst
6 months, better results were obtained with DES, however this superi-
ority disappeared after 2 years, and in some studies the results even
turned in favor of BMS.7,8
In the SOS (Stenting Saphenous Vein Graft) study by Brilakis et al.,
the one-year rates of TLR and TVL in the BMS and DES groups, were
found to be 28% and 5%, 31% and 15% respectively in favor of DES. Mor-
talitywas found to be similar in both groups.6 In the RRİSC (Reduction of
Restenosis with Cypher Sirolimus eluting stent in Saphenous Vein
Grafts) study, the rates of TLR and TVR in 6 months were 32.6% and
13.6% and 27% and 5.3% in BMS and DES groups respectively in favor
of DES. In the late period (32 months later), mortality was found to be
higher in the DES group.7,8 In the STENT (Strategic Transcatheter Evalu-
ation of New Therapies) study, 343 patientswere treatedwith BMS, and
785 with DES, and the results showed that mortality was lower in the
DES group in the second year.9
According to the results of meta analysis, in those to whomDES was
applied, TVR and TLR were found to be lower. Although the short term
consequenceswere in favor of DES, late “catch-up phenomenon” occur-
ring in the long term may result with stent thrombosis and myocardial
infarction.13–16 The reason that the beneﬁt provided in the early period
gradually disappears is related to delayed endothelialization, restenosis,
and stent thrombosis.17,18 The frequency of BMS restenosis has been
reported as 20–40%, and is accompanied by early elastic recoil and late
vascular remodeling and neointimal hyperplasia.5,19 In those to whomts (MACE) Log Rank: 0.413. DES, drug eluting stent; BMS, bare metal stent.
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months.20 It is felt that DES shows its effect by preventing neointimal
thickening in the early stages.
Restenosis is an independent predictor of MACE and long termmor-
tality after PCI. Other predictors of MACE are age of SVG, stent type,
diabetes mellitus, and reference vessel diameter b3.5 mm.9,21–23 Our
study found that diabetes mellitus, stent type and hypertension were
independent predictors of composite MACE. The rate of late restenosis
related TVR after one year tended to be higher in DES patients, resulting
in a comparable rate of composite MACE. These ﬁndings are consistent
with other studies.
Study limitations
This study has several limitations. The retrospective nature of the
study, being a single center study, the small number of patients, and
lack of routine angiographic follow-up are the main limitations of the
study. Also loss to follow up due to time lapse is another limitation of
the study.
Conclusion
Treatment of SVG disease remains a challenge. Although DES were
used in longer lesions, the rates of TVR and MACE at the 1-year evalua-
tion were signiﬁcantly lower in the DES group compared to the BMS
group. However, the initial beneﬁts of DES seen in the ﬁrst year were
not sustained at 2-year follow-up because of recurrent revasculariza-
tions. At-year follow-up, there were no signiﬁcant differences in
composite MACE, MI, mortality and TVR rates. Hypertension, diabetes
mellitus, and type of stent (DES vs. BMS)were identiﬁed as independent
predictors of composite MACE.
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